Table 3 Multivariate analysis for factors associated with overall survival from date of ctDNA analysis in patients with advanced PDAC (N = 94)

Age

 ≥ 68 (N = 47) vs < 68 (N = 47)

11.5 vs 9.0

0.77

–

–

Gender

 Men (N = 51) vs women (N = 43)

9.9 vs 8.9

0.25

–

–

Genomic alterations in ctDNA

 KRAS (N = 48) vs not (N = 46)

7.5 vs 11.4

0.03

1.14 (0.53–2.45)

0.74

 TP53 (N = 45) vs not (N = 49)

8.9 vs 10.1

0.67

Maximum %ctDNA**

 ≥ 0.4% (N = 49) vs < 0.4% (N = 45)

8.9 vs 11.4

0.17

–

–

Total %ctDNA**

 ≥ 0.6% (N = 50) vs < 0.6% (N = 44)

6.3 vs 11.7

0.001

4.35 (1.85–10.24)

0.001

Number of characterized alterations

 ≥ 1 (N = 70) vs none (N = 24)

8.9 vs 11.4

0.27

–

–

Number of systemic therapies prior to ctDNA analysis

 ≥ 1 regimen (N = 40) vs none (N = 54)

6.4 vs 9.9

0.09

2.89 (1.51–5.55)

0.001